Druckversion

Archiv: Mitteilungen

28.08.2014

Daclatasvir zugelassen

Die Europäische Kommission EMA hat Daclatasvir (Daklinza®) als ersten Vertreter der neuen Wirkstoffklasse der NS5A-Inhibitoren bei Erwachsenen mit Hepatitis C zugelassen. Somit ist Daclatasvir ab Zulassung verordnungs- und...[mehr]


28.08.2014

Health Canada Approves Eloctate™, the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A

Biogen Idec Canada | Health Canada Approves Eloctate™, the First Therapy to Extend the Interval...www.newswire.ca– Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five...[mehr]


22.08.2014

WFH communique - Ebola hemorrhagic fever outbreak

WFH communique - Ebola hemorrhagic fever outbreak [EN] - World Federation of Hemophiliawww.wfh.orgAn outbreak of the blood-borne disease Ebola hemorrhagic fever (Ebola HF, also called Ebola virus disease or EVD) is ongoing in...[mehr]


21.08.2014

Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients

Baxter U.S. - Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855,...www.baxter.comBaxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for...[mehr]


20.08.2014

Von Willebrand disease: The nasal spray that could stop the misery of heavy periods

The nasal spray that could stop the misery of heavy periodswww.dailymail.co.ukFor decades, Helen Campbell, 42, from Leeds, suffered from heavy periods and nosebleeds. Her periods could last for 21 days. [mehr]


20.08.2014

Achillion's Hepatitis C Drug Cures All Patients in Mid-stage Trial

Achillion's HCV Drug Cures All Patients in Mid-stage Trialwww.medscape.comAchillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no...[mehr]


19.08.2014

Call for proposal for the Novo Nordisk HERO Research Grant 2014 are open until 31 August 2014

Call for proposal for the Novo Nordisk HERO Research Grant 2014 are open until 31 August 2014 [mehr]


15.08.2014

New Methods May Make CJD Testing Easier

New Methods May Make CJD Testing Easierwww.medpagetoday.comAmplification procedures for abnormally folded prion proteins enabled accurate diagnosis of Creutzfeldt-Jakob disease from nasal and urine samples, two small pilot trials...[mehr]


14.08.2014

Rekombinanter Gerinnungsfaktor VIII aus menschlichen Zellen (Nuwiq®) in der EU zugelassen

Die Europäische Kommission hat die Zulassung für Nuwiq® (simoctocog alfa) zur Behandlung und Prophylaxe bei  Hämophilie A erteilt. Wie die Firma Octapharma mitteilt, ist Nuwiq® das erste FVIII-Konzentrat in Europa,...[mehr]


12.08.2014

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia

Alnylam Pharmaceuticals, Inc. - Alnylam Receives Orphan Drug Designations in the European Union...investors.alnylam.com--(BUSINESS WIRE)-- . (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the (COMP) has...[mehr]


Treffer 1 bis 10 von 978
<< Erste < Vorherige 1-10 11-20 21-30 31-40 41-50 51-60 61-70 Nächste > Letzte >>